Circassia Pharmaceuticals has received a multi-year Innovative Technology contract for its Niox Vero asthma management products from Vizient.
The contract with the largest member-owned health care company in the United States was based on the recommendation of hospital experts with expertise in this category who serve on one of Vizient’s member-led councils.
Circassia’s Niox Vero products are used to assist asthma diagnosis and management, and are indicated in the United States for use in those aged 7 years and older. Niox is based on the discovery that patients with Th2 or type 2 driven airway inflammation, the major underlying cause of asthma, generally have higher than normal levels of nitric oxide in their exhaled breath. By measuring the concentration of this fractional exhaled nitric oxide (FeNO), Niox enables clinicians to evaluate airway inflammation in patients with underlying asthma, aiding diagnosis and helping guide treatment and reduce exacerbations.
Steve Harris, Circassia’s CEO, said that Vizient’s diverse membership and customer base has combined purchasing volume of approximately $100 billion annually, and that the new contract will provide Circassia with a simplified route to access Vizient members as potential new customers. This would help Circassia to expand the number of accounts while offering savings opportunities for Niox users, Harris said.
Circassia stock was 95.00 GBX, +1.30 (+1.39 %) on February 08.
Image: NIOX VERO is a device for assessing airway inflammation in patients with respiratory problems such as asthma.